Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Mark Bernstein

Psychosomatic Medicine Kapolei, HI Medical Doctor

NPI 1770795734 CMS profile 698902

599 Farrington Hwy, Suite 100, Kapolei, HI 96707

Open in the dashboard

General payments

$2,082

99 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Mark Bernstein of Kapolei, HI is reported in the CMS Open Payments database as having received $2,082 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Psychosomatic Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $27 1
2023 General $266 12
2022 General $697 30
2021 General $542 27
2020 General $264 14
2019 General $287 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Bernstein
  • Psychosomatic Medicine median
  • Middle half of Psychosomatic Medicine
  • National median

In program year 2025, general payments to Mark Bernstein were reported at $0. Among 72 Psychosomatic Medicine profiles paid that year, the median was $152 and the middle half received between $47 and $428.

Show as a table
Year Mark Bernstein Psychosomatic Medicine median Middle half National median
2019 $287 $125 $51–$524 $163
2020 $264 $117 $29–$251 $114
2021 $542 $123 $33–$366 $132
2022 $697 $107 $37–$450 $149
2023 $266 $131 $57–$397 $160
2024 $27 $122 $27–$293 $164
2025 $0 $152 $47–$428 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Alkermes, Inc. $466 24 payments
  2. Lundbeck LLC $389 19 payments
  3. Otsuka America Pharmaceutical, Inc. $389 16 payments
  4. AbbVie, Inc. $363 18 payments
  5. Indivior Inc. $126 5 payments
  6. Allergan Inc. $96 6 payments
  7. Sunovion Pharmaceuticals Inc. $84 4 payments
  8. Janssen Pharmaceuticals, Inc $79 3 payments
  9. Teva Pharmaceuticals USA, Inc. $50 2 payments
  10. ITI, Inc. $41 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,082 99 payments
Products named General payments · program years 2019–2024
  1. ARISTADA Cns $446 23 payments
  2. ARISTADA Cns $446 23 payments
  3. ARISTADA INITIO $378 19 payments
  4. VRAYLAR $363 18 payments
  5. ABILIFY MAINTENA $305 12 payments
  6. REXULTI $275 13 payments
  7. ARISTADA Cns $271 14 payments
  8. ARISTADA Cns $271 14 payments
  9. LYBALVI Cns $262 14 payments
  10. LYBALVI Cns $195 10 payments
  11. Other $820 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychosomatic Medicine in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record